643 related articles for article (PubMed ID: 26062437)
1. Edoxaban versus placebo, aspirin, or aspirin plus clopidogrel for stroke prevention in atrial fibrillation. An indirect comparison analysis.
Blann AD; Skjøth F; Rasmussen LH; Larsen TB; Lip GY
Thromb Haemost; 2015 Aug; 114(2):403-9. PubMed ID: 26062437
[TBL] [Abstract][Full Text] [Related]
2. Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study.
Hohnloser SH; Camm J; Cappato R; Diener HC; Heidbuchel H; Lanz HJ; Mont L; Morillo CA; Smolnik R; Yin OQP; Kautzner J
Clin Cardiol; 2018 Apr; 41(4):440-449. PubMed ID: 29663464
[TBL] [Abstract][Full Text] [Related]
3. Net clinical benefit of edoxaban versus no treatment in a 'real world' atrial fibrillation population: A modelling analysis based on a nationwide cohort study.
Blann AD; Banerjee A; Lane DA; Torp-Pedersen C; Lip GY
Int J Cardiol; 2015 Dec; 201():693-8. PubMed ID: 26379097
[TBL] [Abstract][Full Text] [Related]
4. Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF-TIMI48 Trial.
Xu H; Ruff CT; Giugliano RP; Murphy SA; Nordio F; Patel I; Shi M; Mercuri M; Antman EM; Braunwald E
J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26908401
[TBL] [Abstract][Full Text] [Related]
5. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
Ruff CT; Giugliano RP; Braunwald E; Morrow DA; Murphy SA; Kuder JF; Deenadayalu N; Jarolim P; Betcher J; Shi M; Brown K; Patel I; Mercuri M; Antman EM
Lancet; 2015 Jun; 385(9984):2288-95. PubMed ID: 25769361
[TBL] [Abstract][Full Text] [Related]
6. Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
; Connolly SJ; Pogue J; Hart RG; Hohnloser SH; Pfeffer M; Chrolavicius S; Yusuf S
N Engl J Med; 2009 May; 360(20):2066-78. PubMed ID: 19336502
[TBL] [Abstract][Full Text] [Related]
7. Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W).
Healey JS; Hart RG; Pogue J; Pfeffer MA; Hohnloser SH; De Caterina R; Flaker G; Yusuf S; Connolly SJ
Stroke; 2008 May; 39(5):1482-6. PubMed ID: 18323500
[TBL] [Abstract][Full Text] [Related]
8. Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation.
Okumura K; Akao M; Yoshida T; Kawata M; Okazaki O; Akashi S; Eshima K; Tanizawa K; Fukuzawa M; Hayashi T; Akishita M; Lip GYH; Yamashita T;
N Engl J Med; 2020 Oct; 383(18):1735-1745. PubMed ID: 32865374
[TBL] [Abstract][Full Text] [Related]
9. Outcomes and Safety of Very-Low-Dose Edoxaban in Frail Patients With Atrial Fibrillation in the ELDERCARE-AF Randomized Clinical Trial.
Akashi S; Oguri M; Ikeno E; Manita M; Taura J; Watanabe S; Hayashi T; Akao M; Okumura K; Akishita M; Yamashita T
JAMA Netw Open; 2022 Aug; 5(8):e2228500. PubMed ID: 35997978
[TBL] [Abstract][Full Text] [Related]
10. A review of antithrombotic therapy and the rationale and design of the randomized edoxaban in patients with peripheral artery disease (ePAD) trial adding edoxaban or clopidogrel to aspirin after femoropopliteal endovascular intervention.
Tangelder MJ; Nwachuku CE; Jaff M; Baumgartner I; Duggal A; Adams G; Ansel G; Grosso M; Mercuri M; Shi M; Minar E; Moll FL
J Endovasc Ther; 2015 Apr; 22(2):261-8. PubMed ID: 25809373
[TBL] [Abstract][Full Text] [Related]
11. Effect of 15-mg Edoxaban on Clinical Outcomes in 3 Age Strata in Older Patients With Atrial Fibrillation: A Prespecified Subanalysis of the ELDERCARE-AF Randomized Clinical Trial.
Kuroda M; Tamiya E; Nose T; Ogimoto A; Taura J; Imamura Y; Fukuzawa M; Hayashi T; Akao M; Yamashita T; Lip GYH; Okumura K
JAMA Cardiol; 2022 Jun; 7(6):583-590. PubMed ID: 35416910
[TBL] [Abstract][Full Text] [Related]
12. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
; Connolly S; Pogue J; Hart R; Pfeffer M; Hohnloser S; Chrolavicius S; Pfeffer M; Hohnloser S; Yusuf S
Lancet; 2006 Jun; 367(9526):1903-12. PubMed ID: 16765759
[TBL] [Abstract][Full Text] [Related]
13. [Preventing cerebrovascular accidents during atrial fibrillation].
Ederhy S; Meuleman C; Hammoudi N; Janower S; Boccara F; Cohen A
Presse Med; 2005 Oct; 34(18):1315-24. PubMed ID: 16269996
[TBL] [Abstract][Full Text] [Related]
14. Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable.
Connolly SJ; Eikelboom JW; Ng J; Hirsh J; Yusuf S; Pogue J; de Caterina R; Hohnloser S; Hart RG;
Ann Intern Med; 2011 Nov; 155(9):579-86. PubMed ID: 22041946
[TBL] [Abstract][Full Text] [Related]
15. Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease.
Lopes RD; Rao M; Simon DN; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Go AS; Hylek EM; Kowey P; Piccini JP; Singer DE; Chang P; Peterson ED; Mahaffey KW
Am J Med; 2016 Jun; 129(6):592-599.e1. PubMed ID: 26797080
[TBL] [Abstract][Full Text] [Related]
16. Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS.
Alexander JH; Wojdyla D; Vora AN; Thomas L; Granger CB; Goodman SG; Aronson R; Windecker S; Mehran R; Lopes RD
Circulation; 2020 May; 141(20):1618-1627. PubMed ID: 32223444
[TBL] [Abstract][Full Text] [Related]
17. Edoxaban for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
Dzeshka MS; Lip GY
Expert Opin Pharmacother; 2015; 16(17):2661-78. PubMed ID: 26559069
[TBL] [Abstract][Full Text] [Related]
18. Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials?
Duerschmied D; Brachmann J; Darius H; Frey N; Katus HA; Rottbauer W; Schäfer A; Thiele H; Bode C; Zeymer U
Clin Res Cardiol; 2018 Jul; 107(7):533-538. PubMed ID: 29679144
[TBL] [Abstract][Full Text] [Related]
19. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention.
Lamberts M; Gislason GH; Olesen JB; Kristensen SL; Schjerning Olsen AM; Mikkelsen A; Christensen CB; Lip GY; Køber L; Torp-Pedersen C; Hansen ML
J Am Coll Cardiol; 2013 Sep; 62(11):981-9. PubMed ID: 23747760
[TBL] [Abstract][Full Text] [Related]
20. Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry.
Steinberg BA; Kim S; Piccini JP; Fonarow GC; Lopes RD; Thomas L; Ezekowitz MD; Ansell J; Kowey P; Singer DE; Gersh B; Mahaffey KW; Hylek E; Go AS; Chang P; Peterson ED;
Circulation; 2013 Aug; 128(7):721-8. PubMed ID: 23861512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
